reports
Steris Plc: 1 director
A director at Steris Plc sold/sold after exercising options 17,626 shares at 242.559USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
ResMed Inc: 1 director
A director at ResMed Inc sold 2,000 shares at 247.320USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Edwards Lifesciences Corp: 1 director
A director at Edwards Lifesciences Corp sold 17,066 shares at 77.220USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Boston Scientific Corp: 1 director
A director at Boston Scientific Corp sold after exercising options/sold 164,443 shares at 103.690USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
- Research Team ACF
KDST + NLSP Combined Core Investment Case 29052025
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
Resmed Champions Sleep Health as The Official Sleep Partner of The Qat...
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans’ dreams to life over a six-week period. For the first time in 12 years, The Lions squad, alongside an estimated 40,000 fans, will b...
Stryker Corp: 1 director
A director at Stryker Corp sold 1,241 shares at 388.560USD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Stryker declares an $0.84 per share quarterly dividend
Stryker declares an $0.84 per share quarterly dividend Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in ...
Conmed Corp: 1 director
A director at Conmed Corp sold 4,000 shares at 56.942USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Stryker reports first quarter 2025 operating results
Stryker reports first quarter 2025 operating results Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures Org...
Resmed Acquires VirtuOx
Resmed Acquires VirtuOx Acquisition supports Resmed’s growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more a...
Stryker to participate in the Bank of America Securities 2025 Global H...
Stryker to participate in the Bank of America Securities 2025 Global Healthcare Conference Portage, Michigan, April 29, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2025 Global Healthcare Conference on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada. Representing the company will be Preston Wells, Vice President and Chief Financial Officer, and Jason Beach, Vice President, Finance and Investor Relations. Their presentation is scheduled for 1:40 p.m. Pacific Time. A live webcast and replay of the presentation will ...
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 202...
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin ...
Resmed Names Salli Schwartz as Chief Investor Relations Officer
Resmed Names Salli Schwartz as Chief Investor Relations Officer Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairm...
Stryker to announce financial results for its first quarter of fiscal ...
Stryker to announce financial results for its first quarter of fiscal year 2025 Portage, Michigan, April 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2025 on Thursday, May 1, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at that day. The press release will include summary financial information for the company’s first quarter that ended March 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, May 1, 2025, to discuss its first quarter 2025 results. ...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Johnson & Johnson and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 2 April 2025 in which we reassessed the appropriateness of the ratings in the context of ...
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, ...
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosis SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, ™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified,...
Moody's Ratings says J&J's talc overhang remains after court ruling, b...
Moody's Ratings (Moody's) said that Johnson & Johnson's ("J&J") talc overhang remains after its latest talc subsidiary bankruptcy attempt was denied in courts, but its strong business profile and financial flexibility mitigate ongoing litigation pressures. There is no change at this time to J&J's ra...
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location: •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PD...
Stryker completes sale of U.S. spinal implants business
Stryker completes sale of U.S. spinal implants business Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC. “The sale of our spinal implants business enhances our strategic focus, positioning us to meet evolving customer needs and invest where we see the greatest opportunity for innovation and long-term growth,” said Kevin Lobo, Chair and CEO, Stryker. “We remain...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.